Evidence map›Paper›PMID 36406647›Full record

ArticleJGH open : an open access journal of gastroenterology and hepatology2022

Treatment pattern and clinical outcomes in portopulmonary hypertension: A database study in Japan.

Masanori Atsukawa, Masashi Takano, Junichi Omura

Open access · goldAbstract read
In one paragraph

Article in JGH open : an open access journal of gastroenterology and hepatology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Symptom-based portopulmonary hypertension screening questionnaire in Japanese patients with chronic liver disease.JGH open : an open access journal of gastroenterology and hepatology · 2023
    Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Masanori AtsukawaDivision of Gastroenterology and Hepatology Nippon Medical School Tokyo Japan.ORCID https://orcid.org/0000-0003-3374-7111
Masashi TakanoMedical Affairs Division Janssen Pharmaceutical K.K. Tokyo Japan.ORCID https://orcid.org/0000-0002-4625-3762
Junichi OmuraMedical Affairs Division Janssen Pharmaceutical K.K. Tokyo Japan.ORCID https://orcid.org/0000-0002-6015-5739
Nippon Medical School · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and Aim: Portopulmonary hypertension (PoPH) is a complication associated with portal hypertension. Since the epidemiological study in Japan was limited, this study aimed to investigate the characteristics, treatment patterns, and prognosis of PoPH patients in real-world data. Methods: The characteristics and treatment patterns of PoPH ( Results: Among 386 PoPH patients, the Child-Pugh classification of PoPH group comprised patients with Class A (59 [15.3%]), B (109 [28.2%]), and C (42 [10.9%]), and missing (176 [45.6%]). Regarding the feature of PoPH group, the proportion of primary biliary cholangitis (PBC) (13.7%) and splenomegaly (9.8%) was higher compared with portal hypertension w/o PAH group. The survival time of all-cause hospitalization in PoPH group was shorter than portal hypertension w/o PAH group in matched pair cohort ( Conclusion: This was the first study demonstrating that high proportion of PBC and splenomegaly and a greater risk of hospitalization were observed in PoPH patients based on the analysis using administrative claim database.

Indexed as

databaseportal hypertensionportopulmonary hypertensionpulmonary arterial hypertensiontreatment pattern

Identifiers

PMID36406647
PMCPMC9667400
OpenAlexW4306157769

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.